KPV
KPV: A Tripeptide, Transporter & Inflammation Models
Reference check: 7 October 2026
Learn about Lys-Pro-Val, its relationship to alpha-MSH research, and the transporter-dependent findings studied in intestinal and immune-cell models.
KPV is associated with the C-terminal sequence of alpha-MSH; it should not be described as an alpha-casein fragment.
Identify the three residues
KPV stands for lysine, proline and valine. The sequence is discussed as a C-terminal fragment of alpha-melanocyte-stimulating hormone, or alpha-MSH. Defining the sequence matters because short peptides can have similar-sounding names without the same origin or chemistry.
Research on KPV has considered inflammatory signaling and transport into cells. That does not assign the peptide one established clinical effect or make every immune-related catalog description equivalent.
What the transporter study examined
Dalmasso and colleagues investigated PepT1-mediated KPV uptake in cellular systems and its effects in mouse models of colitis. The study linked transport with changes in inflammatory signaling under those experimental conditions. [1]
This distinction is useful: a peptide's ability to reach the relevant intracellular system can be part of the experiment. A result is not necessarily explained by direct activation of a proposed cell-surface receptor.
Context controls the interpretation
Transporter expression, inflammatory state and assay design can influence the response. A finding in one cell type should not be generalized to every tissue or condition without additional evidence.
Changes in signaling markers or cytokine measurements are also different from established clinical improvement. The study model and endpoint should appear alongside any summary of the result.
Avoid converting preclinical work into instructions
KPV may appear as a single compound or a blend ingredient. A paper about KPV alone does not validate the composition, stability or efficacy of a four-component mixture.
This educational overview explains sequence, transport and evidence scope. It does not recommend treatment for inflammatory bowel disease, establish a personal administration method or authenticate a commercial batch from a literature citation.
Questions to bring to the evidence
- Was transporter expression relevant to the observed response?
- Did the study measure a signaling change or a demonstrated clinical outcome?
Sources & further reading
- Dalmasso et al. (2008): PepT1-mediated KPV uptake and inflammationPrimary cell and animal study